VanEck Biotech ETF (BBH) is a healthcare and biotech ETF. As of October 9, 2026, ETF Copilot scores BBH 3.9 out of 10 — highest on Growth (8.8), lowest on Value (1.0). It trades at 27.9 times earnings, against its own median of 23.3. Its ten largest holdings are 73% of the fund.
What stands out in BBH's data
Tracks U.S. biotech pure-plays focused on innovation and development.
Priced higher than most health-care peers — a rich entry point for a sector that lives on binary trial results.
Its 20.9x EBITDA multiple sits well above the category median of 16.5x and its own 14.2x historical median. Top holdings concentration runs at 72.8%.
A focused biotech innovation sleeve, built on breakthroughs rather than broad health care exposure.
Why did BBH move this week? It rose 1.3% in the week to October 9, 2026 — Moderna and Gilead Sciences drove it
BBH rose 1.3% in the week to October 9, 2026. The holdings that moved it most were Moderna (+18.4%), Gilead Sciences (+4.4%) and Amgen (+2.9%); Argenx SE (−10.2%) pushed the other way.
How is BBH rated? ETF Copilot scores VanEck Biotech ETF (BBH) 3.9 out of 10
As of October 9, 2026, ETF Copilot scores VanEck Biotech ETF (BBH) 3.9 out of 10 overall.
ETF Copilot scores (0–10 scale, higher is better):
- Overall: 3.9 / 10
- Growth: 8.8 / 10
- Value: 1.0 / 10
- Risk: 3.0 / 10
- Quality: 1.3 / 10
- Return: 3.3 / 10
Is BBH expensive right now? It trades at 27.9 times earnings, against its own median of 23.3
As of October 9, 2026, BBH is more expensive than 77% of its own last 9 years.
Trailing 12 months, built from BBH's holdings. How we calculate this →
What's inside BBH?
What's inside BBH: Size (Large 81%, Mid 19%, Small 0%); Geography (International 11%, US 89%); AI 3.2%.
What are BBH's top holdings? The ten largest are 73% of the fund
Amgen, Gilead Sciences, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna, Natera, Argenx SE, IQVIA, Revolution Medicines and Illumina are BBH's largest holdings, in that order.
More concentrated than 86% of Health & Biotech ETFs.
Half of BBH's weight sits in its 5 largest positions, and once those weights are taken into account it behaves like 13 equally weighted holdings.
What is BBH's expense ratio? 0.35% a year
As of October 9, 2026, BBH charges 0.35% a year, yields 0.40% and holds $472M in assets across 25 positions.
| Measure | BBH |
|---|---|
| Expense ratio | 0.35% |
| Dividend yield | 0.40% |
| Assets under management | $472M |
| Holdings | 25 |
Expense ratio, dividend yield and assets under management are reported by the fund and refreshed daily. Every other figure on this page is computed by ETF Copilot.
Cite this
ETF Copilot, “VanEck Biotech ETF (BBH) scores and holdings analysis”, as of October 9, 2026.
https://etf-copilot.com/etf/bbh
ETF Copilot Pro unlocks BBH's price and what each holding weighs.
Try Pro free →